Millennium Management
TBPH icon

Millennium Management’s Theravance Biopharma TBPH Stock Holding History

Millennium Management’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-215,500
Closed -$1.59M – 7369
2021
Q3 		$1.59M Buy
+215,500
New +$2.41M ﹤0.01% 4163

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
Irenic Capital Management New York $1.54B AUM 12.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management's TBPH Position: Q1 2026 in Review

Millennium Management sold out of Theravance Biopharma (TBPH) in Q1 2026, closing a stake of 136,978 shares — an estimated $2.56M sold.

Millennium Management first reported a position in TBPH in Q3 2014 and held it in 34 quarters. The position peaked at $7.58M in Q4 2022. 173 funds tracked by Wall St. Rank hold TBPH as of Q1 2026.

  • Millennium Management reported no remaining Theravance Biopharma position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 136,978 Theravance Biopharma shares in Q1 2026, an estimated $2.56M.
  • Millennium Management first reported a position in Theravance Biopharma in Q3 2014 and held it in 34 quarters.
  • Millennium Management's Theravance Biopharma position peaked at $7.58M in Q4 2022.
  • 173 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.